INCY

Incyte Corporation

59.65 USD
-0.07 (-0.12%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Incyte Corporation stock is up 2.74% since 30 days ago. The next earnings date is Apr 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48.39% of the previous 30 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 43% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Feb 18:19 16 Feb, 2024 60.00 CALL 300 119
09 Feb 20:05 16 Feb, 2024 62.50 CALL 600 711
12 Feb 20:08 16 Feb, 2024 60.00 CALL 285 2742
14 Feb 15:56 15 Mar, 2024 65.00 CALL 2300 3621
21 Feb 19:25 19 Apr, 2024 60.00 CALL 100 318
21 Feb 19:26 15 Mar, 2024 65.00 CALL 550 1604
29 Feb 16:45 15 Nov, 2024 57.50 PUT 72 314
29 Feb 16:46 15 Nov, 2024 57.50 PUT 93 314
29 Feb 16:59 15 Nov, 2024 57.50 PUT 86 314
29 Feb 18:30 15 Nov, 2024 57.50 PUT 67 314

About Incyte Corporation

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

  • Jefferies
    Fri Feb 23, 05:52
    buy
    initial
  • JP Morgan
    Wed Feb 14, 13:10
    hold
    downgrade
  • BMO Capital
    Wed Feb 14, 11:34
    hold
    confirm
  • Citigroup
    Wed Feb 14, 10:39
    buy
    confirm
  • RBC Capital
    Wed Feb 14, 10:23
    hold
    confirm
  • Stifel
    Wed Feb 14, 08:54
    hold
    confirm
  • Truist Securities
    Wed Feb 14, 08:20
    buy
    confirm